Kyung Sook Kim – CEO, Corestem, South Korea
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Ahn-Gook Pharmaceutical Co. Ltd has developed and supplied outstanding medicines for the last 45 years, dedicated to developing “advanced pharmaceutical products for health and happiness of the mankind.” As a result of this sustainable effort and growth Ahn-Gook has achieved KOSDAQ enlistment and transparent management as a recognized pharmaceutical developer. Ahn-Gook has set a new vision to realize “new world-class medicine and global marketing by 2020.” In the 21st century, only companies with core technology and key manpower survive. Therefore, Ahn-Gook is accumulating core technology to develop new world-class medicine and fostering key manpower for developing and marketing our new medicines.
Contact details
993-75 Daerim-2-dong Yeongdeungpo-gu, Seoul
TEL +82 2 3289 4200
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
